Five days after regaining the helm at CureVac — and 1 day after controversy erupted — Ingmar Hoerr makes surprise exit
Five days ago, CureVac founder and original CEO Ingmar Hoerr grabbed back the reins at the German biotech, later explaining to us that at that point, with a global coronavirus crisis underway, the company needed a scientist at the helm.
Yesterday, word got out that the Trump administration was trying to co-opt the mRNA tech that CureVac had pioneered, promising it could develop a new vaccine that could be quickly manufactured for millions of people. European authorities were livid at the idea of being squeezed out by the US government.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 76,900+ biopharma pros reading Endpoints daily — and it's free.